Literature DB >> 17539709

Effect of platelet-rich plasma on the healing of intrabony defects treated with an anorganic bovine bone mineral and expanded polytetrafluoroethylene membranes.

Ferenc Döri1, Tamás Huszár, Dimitris Nikolidakis, Nicole B Arweiler, István Gera, Anton Sculean.   

Abstract

BACKGROUND: Regenerative periodontal therapy with a combination of platelet-rich plasma (PRP) + an anorganic bovine bone mineral (ABBM) + guided tissue regeneration (GTR) has been shown to result in significantly higher probing depth reductions and clinical attachment level gains compared to treatment with open flap debridement (OFD) alone, ABBM alone, or GTR alone. However, there are no data evaluating to what extent the use of PRP may additionally enhance the clinical outcome of the therapy compared to treatment with ABBM + GTR. This study aimed to clinically evaluate the effect of PRP on the healing of deep intrabony defects treated with ABBM and GTR by means of a non-resorbable expanded polytetrafluoroethylene (ePTFE) membrane.
METHODS: Twenty-four patients with advanced chronic periodontal disease and displaying one intrabony defect were randomly treated with a combination of either PRP + ABBM + GTR or ABBM + GTR. The following clinical parameters were evaluated at baseline and at 1 year after treatment: plaque index (PI), gingival index (GI), bleeding on probing (BOP), probing depth (PD), gingival recession (GR), and clinical attachment level (CAL). The primary outcome variable was CAL.
RESULTS: No differences in any of the studied parameters were observed at baseline between the two groups. Healing was uneventful in all patients. At 1 year after therapy, the sites treated with PRP + ABBM + GTR showed a reduction in mean PD from 8.6 +/- 1.7 mm to 3.1 +/- 1.3 mm (P <0.001) and a change in mean CAL from 10.3 +/- 1.4 mm to 5.7 +/- 1.6 mm (P <0.001). In the group treated with ABBM + GTR, mean PD was reduced from 8.8 +/- 1.7 mm to 3.1 +/- 1.0 mm (P <0.001), and the mean CAL changed from 10.4 +/- 2.6 mm to 5.9 +/- 1.8 mm (P <0.001). In both groups, all sites gained > or =3 mm of CAL. CAL gains > or =4 mm were measured in 83% (i.e., in 10 of 12 defects) of the cases treated with PRP + ABBM + GTR and in 92% (i.e., in 11 of 12 defects) treated with ABBM + GTR. No statistically significant differences in any of the studied parameters were observed between the two groups at 1-year reevaluation.
CONCLUSION: Within its limits, the present study has shown that, at 1 year after regenerative therapy in periodontal intrabony defects, optimal clinical results were obtained with ABBM + GTR with a non-resorbable barrier, with or without the addition of PRP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17539709     DOI: 10.1902/jop.2007.060349

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  15 in total

1.  Comparison of platelet pellet with or without guided tissue regeneration in the treatment of class II furcation defects in dogs.

Authors:  Gonca Cayir Keles; Burcu Ozkan Cetinkaya; Sancar Baris; Davut Albayrak; Selen Burcak Simsek
Journal:  Clin Oral Investig       Date:  2008-12-20       Impact factor: 3.573

Review 2.  The effect of platelet-rich plasma on clinical outcomes of the surgical treatment of periodontal intrabony defects: A systematic review and meta-analysis.

Authors:  Xinshan Hou; Jingwen Yuan; Absijiang Aisaiti; Yuan Liu; Jin Zhao
Journal:  BMC Oral Health       Date:  2016-08-17       Impact factor: 2.757

3.  Comparative evaluation of clinical efficacy of β-tri calcium phosphate (Septodont-RTR)™ alone and in combination with platelet rich plasma for treatment of intrabony defects in chronic periodontitis.

Authors:  Jyostna Pinipe; Narendra Babu Mandalapu; Sesha Reddy Manchala; Satheesh Mannem; N V S Sruthima Gottumukkala; Suneetha Koneru
Journal:  J Indian Soc Periodontol       Date:  2014-05

4.  Clinical and radiographic evaluation of intra-bony defects in localized aggressive periodontitis patients with platelet rich plasma/hydroxyapatite graft: A comparative controlled clinical trial.

Authors:  Geeti Gupta
Journal:  Contemp Clin Dent       Date:  2014-10

Review 5.  Adjunctive Platelet-Rich Plasma (PRP) in Infrabony Regenerative Treatment: A Systematic Review and RCT's Meta-Analysis.

Authors:  Mubashir Saleem; Flavio Pisani; Faisal Maqbool Zahid; Ioannis Georgakopoulos; Teuta Pustina-Krasniqi; Edit Xhajanka; Maher Almasri
Journal:  Stem Cells Int       Date:  2018-03-19       Impact factor: 5.443

6.  Autologous platelet concentrates for treating periodontal infrabony defects.

Authors:  Massimo Del Fabbro; Lorena Karanxha; Saurav Panda; Cristina Bucchi; Jayakumar Nadathur Doraiswamy; Malaiappan Sankari; Surendar Ramamoorthi; Sheeja Varghese; Silvio Taschieri
Journal:  Cochrane Database Syst Rev       Date:  2018-11-26

7.  Clinical effectiveness of combining platelet rich fibrin with alloplastic bone substitute for the management of combined endodontic periodontal lesion.

Authors:  Lata Goyal
Journal:  Restor Dent Endod       Date:  2014-01-20

Review 8.  Does PRP enhance bone integration with grafts, graft substitutes, or implants? A systematic review.

Authors:  Alice Roffi; Giuseppe Filardo; Elizaveta Kon; Maurilio Marcacci
Journal:  BMC Musculoskelet Disord       Date:  2013-11-21       Impact factor: 2.362

9.  Evaluation of platelet-rich plasma alone or in combination with demineralized freeze dried bone allograft in treatment of periodontal infrabony defects: A comparative clinical trial.

Authors:  Prerna Agarwal; Anirban Chatterjee; Shankar Gokhale; Himanshu Pratap Singh; Abhishek Kandwal
Journal:  J Indian Soc Periodontol       Date:  2016 Jan-Feb

10.  Effects of platelet rich plasma (PRP) on human gingival fibroblast, osteoblast and periodontal ligament cell behaviour.

Authors:  Eizaburo Kobayashi; Masako Fujioka-Kobayashi; Anton Sculean; Vivianne Chappuis; Daniel Buser; Benoit Schaller; Ferenc Dőri; Richard J Miron
Journal:  BMC Oral Health       Date:  2017-06-02       Impact factor: 2.757

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.